Search

Researchers at the University of Tennessee Health Science Center have published a report on their research on colitis. The study focused on the anti-inflammatory properties of a compound called DJ-X-013 in vitro and in an in vivo model of colitis. The researchers found that DJ-X-013 altered cell morphology and expression of inflammatory cytokines in macrophages, suppressed the expression of NF-kB and inflammatory markers, and improved body weight and colon length in mice with colitis. The study suggests that DJ-X-013 could be a potential therapeutic strategy for reducing inflammation and treating colitis. [Extracted from the article]

A study conducted by researchers at Chongqing Medical University in China has found that a high cholesterol diet can worsen colitis, a form of inflammatory bowel disease (IBD). The study used a mouse model and found that a diet supplemented with high levels of cholesterol led to more severe colitis and disruption of the intestinal barrier. The researchers also discovered that a genetic variant associated with higher serum cholesterol levels was linked to a decreased risk of IBD in humans. These findings suggest that cholesterol may play a role in the development and progression of IBD. [Extracted from the article]

A recent study conducted at Kuwait University investigated the role of claudins in the development of ulcerative colitis and the potential therapeutic effects of nobiletin. The study found that altered expression of claudin isoforms disrupts tight junctions, leading to the development of ulcerative colitis. However, treatment with nobiletin reversed these changes and showed potential anti-inflammatory properties. This research provides insights into the pathogenesis of ulcerative colitis and suggests a potential treatment option. [Extracted from the article]

The article investigates the effects of berberine-evodiamine (BBR-EVO) on ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in mice. Topics discussed include the impact of BBR-EVO on reducing UC symptoms and intestinal inflammation, its role in improving gut microbiota and gut-liver axis, and its potential as a therapeutic agent for inflammatory bowel diseases.

The article presents findings from a study, revealing how the order of neonatal colonization by probiotic and pathogenic strains of Escherichia coli affects immune responses. Topics discussed include the role of imbalances in the microbiome in inflammatory bowel disease, the comparative immunomodulatory effects of different E. coli strains, and the significance of bacterial colonization sequence in influencing gut health and immune development.

The article from the National Institute of Immunology reveals how a specific liver gene program driven by Rela and Stat3 exacerbates colitis in mice by affecting bile acid metabolism. Topics discussed include the liver-gut axis, the role of bile acids in inflammation, and the potential of targeting the Rela-Stat3 network for inflammatory bowel disease (IBD) treatment.

The article focuses on a study examining how helminth-derived metabolites can induce tolerogenic dendritic cells to mitigate experimental colitis. Topics include the association between the decline of intestinal helminth infections and increased inflammatory bowel disease (IBD) prevalence, the impact of helminth excretory-secretory products on dendritic cell function, and the potential therapeutic effects of these metabolites in reducing intestinal inflammation.

The article focuses on recent research from Shenzhen University exploring new treatments for inflammatory bowel disease (IBD). Topics include the anti-inflammatory effects of Kumujan B, its impact on key inflammatory markers like IL-1b and IL-6, and its potential as a therapeutic option for IBD based on in vitro and in vivo studies.

A recent study conducted at the First Affiliated Hospital of Wenzhou Medical University in China has explored the role of fibrinogen-like protein 2 (FGL2) in inflammatory bowel disease (IBD). The researchers found that FGL2 plays a crucial role in regulating macrophage polarization, autophagy, and apoptosis, which are important processes in maintaining intestinal homeostasis. The study also revealed that FGL2 deficiency led to an imbalance in gut microbiota structure and bile acid metabolism, resulting in increased susceptibility to experimental ulcerative colitis. The findings suggest that FGL2 could be a potential therapeutic target for IBD. [Extracted from the article]

A recent study conducted by researchers at Zhejiang University in China has found that Chinese bayberry extract may have a therapeutic effect on brain comorbidities related to inflammatory bowel disease (IBD). The study used mice models and found that the administration of the extract improved behavioral markers, reduced oxidative stress in the brain, and decreased the permeability of the blood-cerebrospinal fluid barrier (BCSFB). These findings suggest that Chinese bayberry extract could potentially be used to alleviate IBD-related brain comorbidities. Further research is needed to fully understand the underlying mechanisms. [Extracted from the article]

Researchers at the University of Sao Paulo have conducted a study on the role of mTORC2 signaling in dendritic cells (DCs) in mice with colitis. They found that the lack of mTORC2 signaling in CD11c(+) myeloid cells reduced the severity of colitis and inhibited the migration of DCs to the lymph nodes, resulting in decreased inflammation. The study suggests that targeting mTORC2 in DCs could be a potential strategy to alleviate intestinal inflammatory diseases. The research was supported by various funding organizations and has been peer-reviewed. [Extracted from the article]

A recent report discusses research findings on ulcerative colitis, a chronic intestinal inflammatory disease. The study focuses on the role of interleukin-35 (IL-35), a cytokine with immunomodulatory function, in the treatment of ulcerative colitis. The researchers constructed engineered bacteria expressing IL-35 and tested its effects on a colitis model in mice. They found that IL-35 treatment improved weight loss, bloody stools, and colon pathology in the mice. Additionally, IL-35 increased the expression of T-cell protein tyrosine phosphatase (TCPTP) in macrophages, which may be involved in the mechanisms of IL-35-mediated attenuation of ulcerative colitis. [Extracted from the article]

A report from Mansoura University in Egypt discusses the findings of a study on colitis. The researchers focused on the effects of Moringa oleifera leaf extract on colitis induced by sodium nitrate. The study found that the extract had modulatory effects on the biomarkers P53, Ki-67, and Pcna, which are related to apoptosis and cell proliferation. The research suggests that Moringa oleifera leaf extract may be a promising option for protecting against colitis-induced changes. [Extracted from the article]

A recent study conducted at Massachusetts General Hospital has found that activating cholinergic enteric neurons in the colon can reduce inflammation in experimental colitis. The researchers hypothesized that these neurons possess anti-inflammatory properties and could be a potential target for treating inflammatory bowel disease. The study involved mice with induced colitis, and the results showed that optogenetic activation of cholinergic neurons improved colitis, preserved smooth muscle contractility, protected against neuron loss, and reduced proinflammatory cytokine production. These findings suggest that enteric cholinergic neurons could be explored as a treatment option for inflammatory bowel disease. [Extracted from the article]

A recent report from Nankai University in Tianjin, China discusses the potential of a natural product called 5S-heudelotinone in treating inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC). The researchers found that 5S-heudelotinone modulates the gut microbiota, increases the concentration of short-chain fatty acids, reduces proinflammatory immune cell numbers, and maintains intestinal mucosal integrity. The study suggests that 5S-heudelotinone could be a safe and effective treatment for IBD and CAC. Further research is needed to explore the potential of this natural product. [Extracted from the article]

A recent article published in Acta Pharmaceutica Sinica B discusses how 5S-Heudelotinone can alleviate experimental colitis by shaping the immune system and enhancing the intestinal barrier in a gut microbiota-dependent manner. The study highlights the potential of 5S-Heudelotinone as a safe and effective treatment for inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC). The compound modulates the gut microbiota, increases the concentration of short-chain fatty acids, reduces proinflammatory immune cell numbers, and maintains intestinal mucosal integrity. This research provides a promising strategy for preventing and treating IBD using novel chemical agents. [Extracted from the article]

According to a news report from Gastroenterology Week, a manuscript on the topic of colitis has been withdrawn due to errors in labeling in two figures. The authors are currently conducting experiments to confirm the data presented. The preprint has not undergone peer review and should not be cited as a reference. For more information on this research, readers can visit the website biorxiv.org. [Extracted from the article]

A recent study conducted by researchers at the University of Helsinki in Finland explored the effects of different fat sources in a ketogenic diet on experimental colitis in mice. The study found that both saturated fatty acids and polyunsaturated linoleic acid in the ketogenic diet significantly alleviated colitis symptoms and prevented inflammation-related weight loss. However, the effects were more pronounced with the polyunsaturated linoleic acid. The study suggests that ketogenic diets may have potential as adjunct treatments for gastrointestinal diseases, but further research is needed to fully understand the mechanisms involved. [Extracted from the article]

A study conducted at Wuhan University in China has found that inhibiting the protein HMGB1 can improve colitis in mice by mediating neutrophil extracellular traps (NETs) and macrophage polarization. Inflammatory bowel disease (IBD) is considered a modern intractable disease, and HMGB1 has been identified as a pro-inflammatory cytokine that may contribute to its pathogenesis. The study observed the effects of HMGB1 inhibition on colonic injury, NETs content, macrophage polarization, and inflammatory cells in mice, and found that inhibiting HMGB1 significantly reduced inflammation and improved colonic histopathological morphology and intestinal mucosal barrier function. The research suggests that inhibiting HMGB1 could be a potential therapeutic approach for IBD. [Extracted from the article]

A study conducted by researchers at China Agricultural University aimed to investigate the effects of different forms and components of Limosilactobacillus mucosae (LM) on gut inflammation in a colitis mouse model. The study found that LM cell-free supernatant (LMCS) was the most effective in alleviating body weight loss and increasing the disease activity index score. All forms and components of LM increased the levels of indole-3-acetic acid and reduced the levels of serotonin in the colon. Additionally, LM and LMCS treatments reduced the expression of pro-inflammatory cytokines. These findings can contribute to the optimization of probiotics and the development of dietary strategies for maintaining a healthy gut. [Extracted from the article]

A study conducted by researchers at South China Agricultural University explores the potential benefits of enocyanin, an extract derived from grape peels, in mitigating gut dysbiosis and alleviating experimental colitis. The study found that enocyanin reduced inflammation and improved symptoms such as weight loss and colon shortening in mice with colitis. Additionally, enocyanin restored gut microbiota homeostasis by decreasing the abundance of potentially pathogenic bacterial species. These findings suggest that enocyanin could be further developed as a functional food or additive. [Extracted from the article]

A recent study conducted at the University of California Berkeley has found that a small molecule prolyl hydroxylase (PHD) inhibitor called DPCA can promote the regeneration of the intestinal epithelium, which is crucial for the remission of inflammatory bowel disease (IBD). The researchers used a supramolecular hydrogel to deliver DPCA to mice with colitis, and found that it protected the mice from epithelial erosion and symptoms of colitis. Additionally, a single dose of DPCA administered after disease onset led to accelerated weight gain and complete restoration of healthy tissue architecture in the mice. The study suggests that further investigation of DPCA as a potential treatment for IBD is warranted. [Extracted from the article]

A recent study conducted by researchers at Jiangxi University of Chinese Medicine in Nanchang, China, has found that ginsenoside Rg1, a compound found in ginseng, has potential therapeutic effects for colitis. The study used mice with induced colitis and found that treatment with ginsenoside Rg1 significantly alleviated symptoms and regulated the balance of Tfh cell subsets, which are closely related to inflammatory bowel disease. The researchers also discovered that ginsenoside Rg1 inhibits the TLR/MyD88 signaling pathway, which is involved in the development of colitis. These findings suggest that ginsenoside Rg1 could be a promising treatment option for colitis. [Extracted from the article]

New research from Campinas, Brazil, explores the potential of specialized pro-resolution lipid mediators (SPMs) in treating inflammatory bowel diseases (IBD). The study investigates the effects of the SPM Resolvin D2 (RvD2) and omega-3 polyunsaturated fatty acids in an experimental model of colitis induced by dextran sulfate sodium (DSS). The results show that dietary supplementation with omega-3-rich oil increases RvD2 and its precursor, reduces disease activity, weight loss, and colonic inflammation, and attenuates experimental colitis. The study suggests that this pathway could offer a new therapeutic approach for IBD. [Extracted from the article]

A report from Kindai University in Osaka, Japan, provides new insights into ulcerative colitis. The research focuses on the crosstalk between NOD2 and TLR2, two proteins involved in the immune response to bacterial cell wall components. The study found that NOD2-deficient mice were more susceptible to experimental colitis, while TLR2-deficient mice were more resistant. The researchers also observed differences in gene expression in patients with active ulcerative colitis compared to those in remission. These findings highlight the role of NOD2-TLR2 crosstalk in the development of colitis. [Extracted from the article]

A study conducted at Medical University-Pleven in Bulgaria has found that monoammonium glycyrrhizinate (MAG), a derivative of glycyrrhizic acid, has anti-inflammatory effects on experimental colitis. The study involved injecting MAG into rats with induced colitis and assessing the effects on clinical symptoms, colon damage, and cytokine levels. The results showed that MAG at a dose of 50 mg/kg improved symptoms and reduced colonic inflammatory damage. This research provides evidence that MAG may be effective in treating inflammatory bowel disease. [Extracted from the article]

Researchers from State University Maringa in Brazil have conducted a study on the treatment of experimental colitis using nanoencapsulation of curcuminoids extracted from Curcuma longa L. The researchers found that nanoencapsulated curcuminoids reduced the disease activity index and the activity of inflammatory enzymes in rats with experimental colitis. The minimum effective dose was determined to be 25 mg kg-1. This research provides insights into the potential use of nanoencapsulation for the treatment of colitis. [Extracted from the article]

A recent study conducted by researchers at Anhui Medical University in Hefei, China, explored the potential role of 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) in the protective effects of vitamin D3 against experimental colitis. The study found that vitamin D3 supplementation alleviated colitis symptoms, including oxidative stress and inflammation, in mice. HMGCS2 was up-regulated after vitamin D3 supplementation, and its downregulation was correlated with reduced vitamin D receptor levels in patients with ulcerative colitis. These findings suggest that up-regulating HMGCS2 may be a potential therapeutic strategy for reducing oxidative stress and inflammation associated with colitis. [Extracted from the article]

A recent study conducted by researchers at Renmin Hospital of Wuhan University in China has found that Fusobacterium nucleatum (Fn) infection exacerbates ulcerative colitis (UC). The study investigated the link between Fn-infected intestinal epithelial cell (IEC)-derived exosomes (Fn-Exo) and the progression of UC. The researchers identified differentially expressed miRNAs in Fn-Exo and non-infected IECs-derived exosomes (Con-Exo) and determined the biological role and mechanism of Fn-Exo in UC development. They found that Fn-Exo delivered miR-129-2-3p from Fn-infected IECs into non-infected IECs, leading to epithelial barrier dysfunction and experimental colitis. The study revealed a previously unknown regulatory pathway in the progression of Fn-infectious UC and suggested that exosomal-miR-129-2-3p and TIMELESS may serve as potential diagnostic biomarkers for UC and Fn-high-UC. [Extracted from the article]

A recent report discusses research on colitis, a type of inflammatory bowel disease. The study focused on the role of a specific enzyme called Group 1B Phospholipase A2 (PLA2G1B) in colitis. The researchers found that mice lacking PLA2G1B showed less severe colitis symptoms compared to wild-type mice. This was attributed to an increase in intestinal stem cells for epithelial repair and a reduction in inflammation caused by myeloid cells. The findings suggest that targeting PLA2G1B could be a potential strategy for managing colitis. [Extracted from the article]

A recent study conducted at Kyoto Tachibana University in Japan explored the effects of excessive glucose and fructose intake on the pathogenesis of ulcerative colitis (UC) in rats. The researchers found that rats fed diets high in glucose or fructose exhibited lower weight and colon length, as well as higher severity scores for inflammation compared to rats in the control group. Additionally, the group fed fructose had higher concentrations of inflammatory cytokines in their serum and colonic tissue. These findings suggest that excessive intake of glucose and fructose can worsen intestinal inflammation in UC. [Extracted from the article]

A recent study conducted by researchers at the University of Erlangen-Nuremberg in Germany explored the potential benefits of a flavonoid combination of apigenin and epigallocatechin-3-gallate (EGCG) in the treatment of inflammatory bowel disease (IBD). The study found that the flavonoid combination exhibited a protective effect on the barrier function of the intestinal epithelium and significantly reduced inflammatory levels in both chronic and acute colitis models. Additionally, the flavonoids positively influenced the composition of the gut microbiota. These findings suggest that flavonoids could be a promising adjunctive treatment for IBD in the future. [Extracted from the article]

Researchers at Beijing University of Chinese Medicine have reported new data on ulcerative colitis. The study focused on the role of inflammation-related pyroptosis in the progression of ulcerative colitis and the potential therapeutic effects of b-sitosterol (SIT) on this condition. The researchers found that SIT treatment attenuated the severity of ulcerative colitis by protecting against weight loss, colon damage, and inflammation. SIT also downregulated the expression of pyroptosis-related proteins and enhanced the integrity of the colonic barrier. These findings suggest that SIT could be a potential medication for the treatment of ulcerative colitis. [Extracted from the article]

Keywords for this news article include: Beijing, People's Republic of China, Asia, Autacoids, Biological Factors, Colitis, Colonic Diseases and Conditions, Cytokines, Digestive System Diseases and Conditions, Experimental Colitis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Gram-Positive Asporogenous Rods, Gram-Positive Bacteria, Gram-Positive Rods, Health and Medicine, Inflammation, Intercellular Signaling Peptides and Proteins, Lactobacillaceae, Lactobacillales, Lactobacillus, Peptides, Proteins, Serotonin, TGF-beta Superfamily Proteins, Transforming Growth Factor beta, Transforming Growth Factors, China Agricultural University. [Extracted from the article]

Keywords: Giza; Egypt; Africa; Colitis; Colonic Diseases and Conditions; Digestive System Diseases and Conditions; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Risk and Prevention EN Giza Egypt Africa Colitis Colonic Diseases and Conditions Digestive System Diseases and Conditions Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Risk and Prevention 725 725 1 10/16/23 20231016 NES 231016 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Research findings on Digestive System Diseases and Conditions - Colitis are discussed in a new report. Keywords for this news article include: Giza, Egypt, Africa, Colitis, Colonic Diseases and Conditions, Digestive System Diseases and Conditions, Experimental Colitis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Health and Medicine, Risk and Prevention, Cairo University. [Extracted from the article]

Colitis, Colonic Diseases and Conditions, Connective Tissue Cells, Diet and Nutrition, Digestive System Diseases and Conditions, Experimental Colitis, Fibroblasts, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Health and Medicine, Vitamin D, Vitamins Keywords: Colitis; Colonic Diseases and Conditions; Connective Tissue Cells; Diet and Nutrition; Digestive System Diseases and Conditions; Experimental Colitis; Fibroblasts; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Vitamin D; Vitamins EN Colitis Colonic Diseases and Conditions Connective Tissue Cells Diet and Nutrition Digestive System Diseases and Conditions Experimental Colitis Fibroblasts Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Vitamin D Vitamins 505 505 1 06/26/23 20230626 NES 230626 2023 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Investigators discuss new findings in colitis. [Extracted from the article]

According to news originating from Kolkata, India, by NewsRx correspondents, research stated, "Colitis is a multifaceted disease which is a global threat in the present times. Keywords: Kolkata; India; Asia; Bacterial Polysaccharides; Colitis; Colonic Diseases and Conditions; Digestive System Diseases and Conditions; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Prebiotics EN Kolkata India Asia Bacterial Polysaccharides Colitis Colonic Diseases and Conditions Digestive System Diseases and Conditions Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Prebiotics 640 640 1 06/05/23 20230605 NES 230605 2023 JUN 5 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- A new study on Digestive System Diseases and Conditions - Colitis is now available. [Extracted from the article]

Keywords for this news article include: Pennsylvania State University (Penn State), University Park, Pennsylvania, United States, North and Central America, Inflammation, Gastroenteritis, Selenoprotein W, Gastroenterology, Health and Medicine, Experimental Colitis, Colonic Diseases and Conditions, Digestive System Diseases and Conditions, Gastrointestinal Diseases and Conditions. Colitis, Colonic Diseases and Conditions, Digestive System Diseases and Conditions, Experimental Colitis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Health and Medicine, Inflammation, Proteins, Selenoprotein W, Selenoproteins Keywords: Colitis; Colonic Diseases and Conditions; Digestive System Diseases and Conditions; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Inflammation; Proteins; Selenoprotein W; Selenoproteins EN Colitis Colonic Diseases and Conditions Digestive System Diseases and Conditions Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Inflammation Proteins Selenoprotein W Selenoproteins 416 416 1 05/15/23 20230515 NES 230515 2023 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Data detailed on colitis have been presented. [Extracted from the article]

Bowel Diseases and Conditions, Colitis, Colonic Diseases and Conditions, Digestive System Diseases and Conditions, Experimental Colitis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Genetics, Health and Medicine, Inflammatory Bowel Disease, Risk and Prevention Keywords: Bowel Diseases and Conditions; Colitis; Colonic Diseases and Conditions; Digestive System Diseases and Conditions; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Genetics; Health and Medicine; Inflammatory Bowel Disease; Risk and Prevention EN Bowel Diseases and Conditions Colitis Colonic Diseases and Conditions Digestive System Diseases and Conditions Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Genetics Health and Medicine Inflammatory Bowel Disease Risk and Prevention 600 600 1 04/24/23 20230425 NES 230425 2023 APR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- New study results on bowel diseases and conditions have been published. [Extracted from the article]

In this study, the effect of curcumin on experimental colitis-induced necroptosis of intestinal epithelial cells was investigated, and its molecular mechanism was further explored. Keywords: Alkanes; Aromatic Hydrocarbons; Catechols; Colitis; Colonic Diseases and Conditions; Curcumin; Diarylheptanoids; Digestive System Diseases and Conditions; Epithelial Cells; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Hydrocarbons; Necroptosis; Organic Chemicals EN Alkanes Aromatic Hydrocarbons Catechols Colitis Colonic Diseases and Conditions Curcumin Diarylheptanoids Digestive System Diseases and Conditions Epithelial Cells Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Hydrocarbons Necroptosis Organic Chemicals 73 73 1 04/24/23 20230425 NES 230425 2023 APR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- New study results on colitis have been published. [Extracted from the article]

Keywords: Colitis; Colonic Diseases and Conditions; Cyclohexanols; Digestive System Diseases and Conditions; Dimethylamines; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Tramadol EN Colitis Colonic Diseases and Conditions Cyclohexanols Digestive System Diseases and Conditions Dimethylamines Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Tramadol 303 303 1 04/10/23 20230413 NES 230413 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- A new study on colitis is now available. To study the effect of those analgesics in colitis mouse models, acute and chronic colitis was induced in female C57BL6 mice by DSS administration in the drinking water. [Extracted from the article]

Keywords: Hamilton; Canada; North and Central America; Autacoids; Biogenic Amines; Biological Factors; Colitis; Colonic Diseases and Conditions; Digestive System Diseases and Conditions; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Organic Chemicals; Serotonin; Tryptamines EN Hamilton Canada North and Central America Autacoids Biogenic Amines Biological Factors Colitis Colonic Diseases and Conditions Digestive System Diseases and Conditions Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Organic Chemicals Serotonin Tryptamines 185 185 1 04/03/23 20230404 NES 230404 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Current study results on Digestive System Diseases and Conditions - Colitis have been published. Keywords for this news article include: Hamilton, Canada, North and Central America, Autacoids, Biogenic Amines, Biological Factors, Colitis, Colonic Diseases and Conditions, Digestive System Diseases and Conditions, Experimental Colitis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Health and Medicine, Organic Chemicals, Serotonin, Tryptamines, McMaster University. [Extracted from the article]

Colitis, Colonic Diseases and Conditions, Digestive System Diseases and Conditions, Experimental Colitis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Health and Medicine, Inflammatory Bowel Diseases and Conditions, Ulcerative Colitis Keywords: Colitis; Colonic Diseases and Conditions; Digestive System Diseases and Conditions; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Inflammatory Bowel Diseases and Conditions; Ulcerative Colitis EN Colitis Colonic Diseases and Conditions Digestive System Diseases and Conditions Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Inflammatory Bowel Diseases and Conditions Ulcerative Colitis 237 237 1 04/03/23 20230404 NES 230404 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Data detailed on ulcerative colitis have been presented. [Extracted from the article]

Keywords: Colitis; Colonic Diseases and Conditions; Cytokines; Digestive System Diseases and Conditions; Epithelial Cells; Experimental Colitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Inflammatory Bowel Disease; Intercellular Signaling Peptides and Proteins EN Colitis Colonic Diseases and Conditions Cytokines Digestive System Diseases and Conditions Epithelial Cells Experimental Colitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Inflammatory Bowel Disease Intercellular Signaling Peptides and Proteins 435 435 1 03/27/23 20230327 NES 230327 2023 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Data detailed on inflammatory bowel disease have been presented. Mice with intestinal epithelial cell-specific knockout of Cish (CishDIEC) and Cish-floxed mice were administered dextran sodium sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS) to induce colitis. [Extracted from the article]